The hypothesis of this study is that treatment with Trichuris suis ova will be safe and effective as an oral treatment of patients with relapsing multiple sclerosis.

Inclusion Criteria:

• age between 19 and 55 years
• relapsing course of multiple sclerosis (relapsing-remitting or secondary progressive MS with relapses
• duration of the disease of at least 1 year
• no disease modifying therapy or unchanged immunomodulatory therapy for the last 3 months
• at least 2 documented relapses during the last 24 months with the last relapse within the last 12 months

Exclusion Criteria:

• pregnancy or period of breastfeeding or missing adequate contraceptive protection for female premenopausal patients
• relapse in the last month prior enrolment
• treatment with steroids in the last 30 days
• previous treatment with mitoxantroneduring the last year
• previous treatment with cyclophosphamide or other intensive immunosuppression, total irradiation
• treatment with glatiramer acetate, azathioprine, IVIG or any other immunosuppressive or immunomodulatory drug apart from interferon-beta in the 6 months prior to enrolment
• cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, instable or advanced ischemic heart disease (CCS III or IV), malignant hypertension
• diabetes mellitus and other autoimmune diseases
• history of renal insufficiency
• stay in tropical areas during the last 3 months
• eosinophilia in the blood (> 0,45 billion/l)
• concurrent systemic infections